VIR Vir Biotechnology, Inc.

NASDAQ
$9.24

Vir Biotechnology, Inc. (VIR) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.80 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.7% since its last earnings release on August 5, 2026.

Vir Biotechnology Missed Consensus Estimates
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.80)
Rev est $850K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $8.91

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vir Biotechnology, Inc.

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.

Sector

Healthcare

Industry

Biotechnology